157 results
8-K
EX-10.1
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
and reasonably incurred by Mayne, its sublicensees or any of their respective Affiliates selling such Products:
(a) customer directed commissions
8-K
EX-10.2
TXMD
TherapeuticsMD Inc
5 Dec 22
TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma
7:31am
Information” means marketing, advertising, and promotional and similar information, including sales and customer information, that is existing, owned … or any Ancillary Agreement, from and after the NDA Transfer Date, Purchaser (i) shall be responsible for handling and responding to all customer
SC TO-T/A
wfy hwre41p
6 Jul 22
Third party tender offer statement (amended)
6:23am
SC TO-T/A
ygow4eq
23 Jun 22
Third party tender offer statement (amended)
4:07pm
SC TO-T/A
EX-99
cjpb48fx211atszg
23 Jun 22
Third party tender offer statement (amended)
4:07pm
8-K
EX-2.1
dy2ogmfrwsodpd7nq0ma
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-10.2
1bg74ub j8il2
31 May 22
TherapeuticsMD and EW Healthcare Partners
6:47am
8-K
EX-99.1
cxyeo7t61839xf2
20 May 22
Regulation FD Disclosure
10:30am
POS AM
v3z am6b0k
23 Mar 22
Prospectus update (post-effective amendment)
6:06pm
POSASR
hgbcm
23 Mar 22
Automatic shelf registration (post-effective amendment)
4:37pm
8-K
EX-2.1
9er6pwz55
10 Mar 22
TherapeuticsMD Announces Fourth Quarter 2021 Financial Results
7:15am
SC TO-I
EX-99
y3zkr45vdy u9hc
26 Aug 21
Issuer tender offer statement
4:55pm